Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01485393
Recruitment Status : Completed
First Posted : December 5, 2011
Results First Posted : October 8, 2019
Last Update Posted : October 8, 2019
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Oluwaseun Johnson-Akeju, MD, MMSc, Massachusetts General Hospital

Tracking Information
First Submitted Date  ICMJE November 30, 2011
First Posted Date  ICMJE December 5, 2011
Results First Submitted Date  ICMJE January 4, 2019
Results First Posted Date  ICMJE October 8, 2019
Last Update Posted Date October 8, 2019
Study Start Date  ICMJE January 2015
Actual Primary Completion Date January 29, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 7, 2019)
Change in Sleep Quality [ Time Frame: Approximately 8 hours ]
Sleep quality will be assessed objectively through EEG measures (changes from baseline in length of non-REM sleep, length of REM sleep, and length of N3 sleep--all assessed in minutes) and subjectively, utilizing a post sleep questionnaire to assess the difference in quantity of sleep (minutes) from baseline. Sleep quality is directly related to these measures of sleep quantity.
Original Primary Outcome Measures  ICMJE
 (submitted: December 1, 2011)
Subjective and objective measures of sleep quality [ Time Frame: Approximately 8 hours ]
Sleep quality will be assessed by both objective and subjective measures. The objective measures will comprise of total sleep time, number of awakenings overnight, sleep latency, normal sleep architecture on EEG. Subjective measures will utilize a post sleep questionnaire to assess the subjects feelings of being well rested.
Change History Complete list of historical versions of study NCT01485393 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 7, 2019)
Performance on a Psychomotor Vigilance Test (PVT) After Waking up From Sleep [ Time Frame: Approximately 30 minutes after waking up ]
The PVT is a measure of reaction time. It is measured as Lapse 400, which is the number of responses on the PVT greater than 400 milliseconds.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 1, 2011)
Performance on a word-pair cognitive task after waking up from sleep [ Time Frame: within 1-2hrs after waking up ]
The word pair task is a cognitive task geared towards understanding the effects of sleep on memory consolidation.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep
Official Title  ICMJE Pilot Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep
Brief Summary The purpose of this study is to determine whether dexmedetomidine can be used to induce normal physiological sleep in humans.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Patients will receive both interventions in a randomized order.
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Insomnia
Intervention  ICMJE
  • Drug: Dexmedetomidine
    A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
    Other Name: Precedex
  • Drug: Zolpidem
    12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
Study Arms  ICMJE
  • Experimental: Healthy Control Subjects: Zolpidem, Then Dexmedetomidine
    This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
    Interventions:
    • Drug: Dexmedetomidine
    • Drug: Zolpidem
  • Experimental: Healthy Control Subjects: Dexmedetomidine, Then Zolpidem
    This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
    Interventions:
    • Drug: Dexmedetomidine
    • Drug: Zolpidem
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 7, 2019)
10
Original Estimated Enrollment  ICMJE
 (submitted: December 1, 2011)
30
Actual Study Completion Date  ICMJE June 29, 2018
Actual Primary Completion Date January 29, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Primary Inclusion Criteria for "Insomniac" subjects:

Subjects will be deemed "Insomniacs" if they suffer from any of the following:

  1. Subject will be required to meet the criteria for insomnia, set by the International Classification of Sleep Disorders, which requires that a patient have difficulty initiating or maintaining sleep that is not accounted for by another sleep disorder, neurologic or psychiatric disorder or substance or medication.
  2. Subject will be required to not be on any current pharmacological sleep disorder treatment.
  3. Between the ages of 18 and 35 years.
  4. Not taking any prescription medications that alter sleep, cognitive functions, or both.

Exclusion Criteria:

Primary Exclusion Criteria for "Healthy" control subjects:

  1. Abnormal sleep habits:

    • sleeping less than 5 hours each night;
    • going to sleep before 9:00 PM or after 2:00 AM on a regular basis; or
    • Waking up before 5:00 AM or after 10:00 AM on a regular basis. This will be objectively assessed by wrist actigraphy measured for a 1-week duration prior to the first study night.
  2. A sleep latency greater than 60 minutes, greater than 3 awakenings per night. This will also be objectively assessed by wrist actigraphy.
  3. A score greater than or equal to 10 on the Epworth Sleepiness Scale.
  4. Takes medication that alters sleep, cognitive function, or both.
  5. Has a history of a known neurological or psychiatric problem.
  6. Younger than 18 or older than 35 years of age.
  7. Known or suspected sleep disorder(s).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 35 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01485393
Other Study ID Numbers  ICMJE 2011P-000715
DP1OD003646 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Oluwaseun Johnson-Akeju, MD, MMSc, Massachusetts General Hospital
Study Sponsor  ICMJE Massachusetts General Hospital
Collaborators  ICMJE National Institutes of Health (NIH)
Investigators  ICMJE Not Provided
PRS Account Massachusetts General Hospital
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP